ReviewPharmacogenomics2013
Pharmacogenomics in early-phase clinical development.
Review in Pharmacogenomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Intra-Target Microdosing - A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans.Clinical and translational science · 2017Trial
- Review
- PGxDB: an interactive web-platform for pharmacogenomics research.Nucleic acids research · 2025Article
- Genomics-driven drug repurposing and novel targets identification for sickle cell disease in Saudi patients.Frontiers in bioinformatics · 2025Article
- Pharmacogenomics in clinical trials: an overview.Frontiers in pharmacology · 2023Article
- Article
- PharmGKB, an Integrated Resource of Pharmacogenomic Knowledge.Current protocols · 2021Article
- Genome-based therapeutic interventions for β-type hemoglobinopathies.Human genomics · 2021Review
- Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020).Journal of personalized medicine · 2021Article
- COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics.Nucleic acids research · 2021Article
- Attitudes of healthy volunteers to genetic testing in phase 1 clinical trials.F1000Research · 2021Article
- Metabolomics in Radiation Biodosimetry: Current Approaches and Advances.Metabolites · 2020Review
- Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine.Metabolites · 2020Review
- Survey of physicians' views on the clinical implementation of pharmacogenomics-based personalized therapy.Translational and clinical pharmacology · 2020Article
- Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables.Frontiers in pharmacology · 2020Review
- Factors Influencing Participation in Biospecimen Research among Parents of Youth with Mental Health Conditions.Public health genomics · 2020Article
- Drug-Placebo Additivity in Randomized Clinical Trials.Clinical pharmacology and therapeutics · 2019Article
- Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.Clinical pharmacology and therapeutics · 2018Review
- Pharmacogenetics and Psychiatric Care: A Review and Commentary.Journal of mental health & clinical psychology · 2018Article
- The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.Clinical and translational science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pharmacogenomics (PGx) offers the promise of utilizing genetic fingerprints to predict individual responses to drugs in terms of safety, efficacy and pharmacokinetics. Early-phase clinical trial PGx applications can identify human genome variations that are meaningful to study design, selection of participants, allocation of resources and clinical research ethics. Results can inform later-phase study design and pipeline developmental decisions. Nevertheless, our review of the clinicaltrials.gov database demonstrates that PGx is rarely used by drug developers. Of the total 323 trials that included PGx as an outcome, 80% have been conducted by academic institutions after initial regulatory approval. Barriers for the application of PGx are discussed. We propose a framework for the role of PGx in early-phase drug development and recommend PGx be universally considered in study design, result interpretation and hypothesis generation for later-phase studies, but PGx results from underpowered studies should not be used by themselves to terminate drug-development programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.